Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ CaliforniafiledCriticalUniv California
Publication of MX9305138ApublicationCriticalpatent/MX9305138A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Esta invención se relaciona con la aplicación de lípidos y formulaciones de lípidos y con el tratamiento de pacientes que adolecen de enfermedades o transtornos de la piel o de la membrana mucosa que exhiben hiperproliferación epidérmica y desgarramientos de la función de barrera.This invention relates to the application of lipids and lipid formulations and to the treatment of patients suffering from diseases or disorders of the skin or mucous membrane that exhibit epidermal hyperproliferation and tears of barrier function.
MX9305138A1992-09-291993-08-25
LIPIDS FOR EPIDERMIC HUMIDIFICATION AND REPAIR OF THE BARRIER FUNCTION.
MX9305138A
(en)
Preparations for the application of anti-inflammatory agents, especially antiseptics and / or agents that promote healing of wounds in the upper respiratory tract and / or the ear
Pharmaceutical composition that has marked antitumor activity and / or reduced side effects containing an antitumor agent and a derivative of hydroxy acid
NON-THERAPEUTIC USE OF AT LEAST AN ANTAGONIST OF THE PEPTIDE DERIVED FROM THE CALCITONINE GENE IS TO SAY AN ANTAGONIST OF CGRP, USE OF SUCH ANTAGONIST FOR THE PREPARATION OF A COMPOSITION THAT IS A DERMATOLOGICALLY COMPUTATION AND A PHARMACEUTICAL PRODUCT TOPIC THAT INCLUDES SUCH ANTAGONIST
PHARMACEUTICAL COMPOSITION THAT INCLUDES AN ALCANOIL L-CARNITINE IN COMBINATION WITH A POLYINSATURED FATTY ACID OF THE OMEGA-3 SERIES FOR THE PREVENTION AND TREATMENT OF LIPID METABOLISM DISORDERS.